CCA
MCRB icon

Clearwater Capital Advisors’s Seres Therapeutics MCRB Stock Holding History

Clearwater Capital Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-545
Closed -$25.9K – 158
2023
Q3 		$25.9K Sell
545
-73
-12% -$5.57K ﹤0.01% 139
2023
Q2 		$59.2K Hold
618
– – 0.01% 146
2023
Q1 		$70.1K Hold
618
– – 0.01% 149
2022
Q4 		$69.2K Hold
618
– – 0.01% 156
2022
Q3 		$79K Hold
618
– – 0.01% 151
2022
Q2 		$42K Hold
618
– – 0.01% 147
2022
Q1 		$88K Buy
618
+60
+11% +$9.23K 0.01% 164
2021
Q4 		$93K Buy
+558
New +$88.7K 0.01% 166

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clearwater Capital Advisors's MCRB Position: Q4 2023 in Review

Clearwater Capital Advisors sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 545 shares — an estimated $25.9K sold.

Clearwater Capital Advisors first reported a position in MCRB in Q4 2021 and held it in 8 quarters. The position peaked at $93K in Q4 2021. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • Clearwater Capital Advisors reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Clearwater Capital Advisors sold 545 Seres Therapeutics shares in Q4 2023, an estimated $25.9K.
  • Clearwater Capital Advisors first reported a position in Seres Therapeutics in Q4 2021 and held it in 8 quarters.
  • Clearwater Capital Advisors's Seres Therapeutics position peaked at $93K in Q4 2021.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Clearwater Capital Advisors's 13F filing for Q4 2023, filed 7 Feb 2024.